> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Positive Phase 3 Results for Moderna Flu Vaccine
- URL: https://www.fdaweb.com/positive-phase-3-results-for-moderna-flu-vaccine/
- Published: 2025-07-07T12:00:00.000Z
- Updated: 2026-09-14T15:15:38.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159444

Moderna says its mRNA-1010 investigational seasonal flu vaccine achieved the most stringent superiority criterion prespecified in a Phase 3 efficacy trial that tested it against a licensed standard-dose influenza vaccine in adults aged 50 and older. A company [statement](https://investors.modernatx.com/news/news-details/2025/Moderna-Announces-Positive-Phase-3-Results-for-Seasonal-Influenza-Vaccine/default.aspx?ref=fdaweb.com) says that in a previous Phase 3 study, the vaccine demonstrated superior seroconversion rates and geometric mean titer ratios against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal flu vaccines.